Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy

Abstract

The mTORC1 signaling pathway is a critical regulator of cell growth and is hyper activated in many different cancers. Rapamycin, an allosteric inhibitor of mTORC1, has been approved for treatment ...